Ticker: CNC

Centene

Healthcare Healthcare Medical - Healthcare Plans

Price 63.40

Reco Sell Potential 43 Risk 70 Updated 2026-07-26

Official website

Forecast impact

neutral

Target +23.0% target fill 81.3%

Reaction D5 -1.57% · D10 -5.44%

Impact Potential 0 · Risk 0 valid until 2026-08-13

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Centene Corporation operates in the healthcare sector, providing managed care services to individuals and families. Its core products include Medicaid and Medicare programs, as well as health insurance plans for the uninsured. Major business segments encompass government-sponsored healthcare programs, with primary revenue sources derived from premiums and service fees. The company focuses on improving health outcomes and reducing costs through integrated care solutions.

Investment Profile

Centene's stock is positioned for balanced investors, reflecting a focus on stability and moderate growth potential. The company has shown resilience in revenue growth, though it currently lacks a dividend yield. Its investment profile suggests a moderate risk level, appealing to those seeking a combination of growth and value without excessive volatility.

Category: Healthcare Sector: Healthcare Industry: Medical - Healthcare Plans Investment style: Growth Horizon: Medium-term Company type: Blue Chip Company type: Market Leader Experience: Basic

Fundamental metrics (experimental) Updated: 2026-07-23

EPS (TTM) — earnings per share for the last 12 months, $: -13.12
Revenue QoQ — quarter-over-quarter revenue growth: 0.4%
EPS surprise: 51.1%
20d volatility: 2.3%

AI recommendation changes

Date	Before	After	Reason
2026-07-24	Buy	Sell	Weak fundamentals and negative momentum raise concerns.
2026-07-22	Hold	Buy	Strong momentum and positive EPS surprise indicate growth potential.
2026-06-25	Sell	Hold	Strong momentum but fundamental weaknesses persist.
2026-06-17	Hold	Sell	Weak fundamentals and high risk; uncertain momentum.
2026-06-09	Buy	Hold	Strong momentum, but fundamentals show significant weakness.
2026-05-30	Hold	Buy	Strong momentum and positive EPS surprise support growth outlook.
2026-05-08	—	Hold	Strong recent performance, but fundamentals show weakness.
2026-05-08	Hold	Hold	Компания показывает сильный рост за последние 20 и 60 дней, что свидетельствует о положительной динамике. Несмотря на отрицательный EPS, высокий сюрприз по доходам и улучшение квартальных показателей указывают на потенци
2026-03-29	Hold	Sell	scenario_deterioration
2026-02-06	Buy	Hold	Компания показывает сильный рост за последние 120 дней, но недавние колебания цен и отсутствие данных о прибыли и выручке вызывают опасения. Рекомендуется удерживать акции до получения более ясной картины финансовых пока
2026-01-30	Hold	Buy	Компания демонстрирует сильный рост за последние 120 дней, что указывает на положительные перспективы. Однако волатильность и отсутствие данных по EPS и дивидендам требуют осторожности.
2026-01-29	Buy	Hold	Компания показывает сильный рост за последние 120 дней, однако недавнее снижение на 7.42% за 5 дней вызывает опасения. Рекомендуется удерживать акции до прояснения ситуации на рынке.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-07-14	Truist Financial	Target Raised	71 → 78	68.29
2026-07-13	Wells Fargo	Target Raised	56 → 69	67.35
2026-07-07	Raymond James	Target Raised	60 → 75	66.05
2026-06-23	RBC Capital	Update	— → 70	63.67
2026-06-08	Mizuho Securities	Target Raised	58 → 63	62.33
2026-06-04	Morgan Stanley	Target Raised	50 → 57	59.55
2026-06-01	Truist Financial	Target Raised	58 → 71	59.585
2026-05-26	Barclays	Target Raised	63 → 75	57.645
2026-05-22	UBS	Target Raised	55 → 61	57.77
2026-05-20	Mizuho Securities	Target Raised	50 → 58	59.15
2026-05-20	Deutsche Bank	Rating Upgraded	— → 80	59.15
2026-04-29	Truist Financial	Target Raised	49 → 58	52.69
2026-04-29	Oppenheimer	Target Raised	45 → 58	49.57
2026-04-29	Goldman Sachs	Target Raised	32 → 40	49.57
2026-04-29	Barclays	Target Raised	54 → 63	49.57
2026-04-29	Raymond James	Update	— → 60	49.57
2026-04-28	Cantor Fitzgerald	Rating Upgraded	— → 60	49.57

News Page 1 of 1

Centene (CNC) Announces Voluntary Separation Program Amid Cost-Cutting Measures

06/15/2026, 01:37 PM business downsizing healthcare Centene

Centene is offering buyouts to some employees as part of its strategy to manage rising medical costs and declining membership, which could signal further workforce reductions if targets are not met. This move reflects broader challenges in the healthcare sector, particularly for Medicaid providers.

Dow Jones Industrial Average Hits Record High as Health-Care Stocks Lead Market Gains

06/05/2026, 05:34 AM business review healthcare UnitedHealth Humana Centene Eli Lilly

Despite a decline in chip stocks, the U.S. stock market saw significant gains, with the Dow Jones Industrial Average reaching a new record, driven largely by strong performance in the health-care sector.

Analysts Morgan Stanley identify 'dividend hopefuls' poised for strong performance with potential payouts

05/29/2026, 12:34 PM investing research Analysts: analysts, Morgan Stanley healthcare consumer Deckers Outdoor Duolingo Centene

Morgan Stanley identifies several companies that could significantly enhance investor returns by initiating dividend payments, highlighting their potential for outsized performance in the market.